



Henriette Richter
Managing Partner
Sofinnova Partners

Henriette Richter is Managing Partner at Sofinnova Partners. She joined as Partner in 2014 from Novo Seeds (part of Novo A/S) where she was involved in the establishment of the group in 2007. While at Novo Seeds Henriette was instrumental in the creation, financing and building of companies such as Cytoguide, Orphazyme, Avilex Pharma, EpiTherapeutics (sold to Gilead) and Lysogene.

Henriette is a scientist by training and started her career at Novo Nordisk conducting her PhD in the area of obesity and GH signalling.

Before joining Sunstone Capital in 2004, Henriette was a postdoctoral fellow at the MIT Center for Cancer Research (MA).

Henriette invested in and is or has been a board member of Asceneuron (CH), Delinia (sold to Celgene for up to \$775 million), iOmx, Nodthera, Comet Therapeutics and Twentyeight-Seven Therapeutics.

